• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Intraventricular alteplase use associated with a minimal reduction in parenchymal intracerebral hemorrhage volume in patients with intracerebral hemorrhage and intraventricular hemorrhage

byYuchen DaiandMichael Pratte
December 7, 2021
in Emergency, Imaging and Intervention, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with spontaneous intracerebral hemorrhage and intraventricular hemorrhage, intraventricular alteplase use was associated with a small reduction in the parenchymal intracerebral hemorrhage volume.

2. However, no association was observed between change in intracerebral hemorrhage volume and improved functional outcomes or mortality.

Evidence Rating Level: 2 (Good)

Study Rundown: The volume of intracranial blood in patients with spontaneous intracerebral hemorrhage (ICH) is one of the factors associated with poor outcomes and overall mortality. A recent randomized clinical trial, CLEAR III, found that the use of intraventricular thrombolysis reduced intraventricular hemorrhage (IVH) volume in patients with spontaneous ICH leading to decreased mortality. However, it is unclear if a similar association between intraventricular thrombolytic therapy and parenchymal ICH volume exists. This cohort study, a post hoc analysis of CLEAR III, assessed the association between intraventricular alteplase use and ICH volume, subsequently evaluating the association between a change in parenchymal ICH volume and long-term disability and functional outcomes. The primary endpoint was the change in parenchymal ICH volume between the hematoma stability and size on computed tomography imaging at the end of treatment. Secondary endpoints were a modified Rankin Scale score higher than 3 and mortality assessed at 6 months. Among 454 patients with ICH and IVH, intraventricular alteplase use was associated with a small reduction in the parenchymal ICH volume. However, there was no association between change in parenchymal ICH volume and improved functional outcomes or mortality. Thus, the authors recommend considering intraventricular thrombolysis in scenarios with moderate to large ICH with IVH. A limitation of this study was that by using data from the CLEAR III trial where only patients with small parenchymal ICH volumes were included, the generalizability of the study findings will be limited to this specific patient population.

Click to read the study in JAMA Network Open

Relevant Reading: Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

In-Depth [prospective cohort]: This post hoc exploratory study included 454 patients (254 men [55.9%]; mean [SD] age, 59 [11] years) with ICH and IVH from the CLEAR III trial between September 2009 to January 2015, with data analysis completed in June 2021. Among them, 230 (50.7%) patients were randomized to receive intraventricular alteplase and 224 (49.3%) to receive normal saline. Patients with primary IVH were excluded. Overall, patients who received alteplase had a greater mean (SD) reduction in parenchymal ICH volume compared to those that received saline (1.8 [0.2] mL vs 0.4 [0.1] mL; P < .001). The primary analysis found that alteplase use was associated with a change in the parenchymal ICH volume in both the unadjusted analysis per 1-mL change (β, 1.37; 95%CI, 0.92-1.81; P < .001) and multivariable linear regression analysis (β, 1.20; 95%CI, 0.79-1.62; P < .001). The secondary analyses found no association between change in parenchymal ICH volume and poor outcome (OR, 0.97; 95%CI 0.87-1.10; P = .64) or mortality (OR, 0.97; 95%CI 0.99-1.08; P = .59).

RELATED REPORTS

Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age

#VisualAbstract: Thrombectomy alone is inferior to thrombectomy plus alteplase for acute ischemic stroke

Intravenous tenecteplase non-inferior to alteplase for thrombolysis in acute ischemic stroke

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: alteplaseHemorrhagic Strokeischemic strokestroke
Previous Post

Smelling and tasting milk alongside tube feeding does not improve weight in preterm infants

Next Post

Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

RelatedReports

Patient Basics: Atherosclerosis
Chronic Disease

Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age

August 5, 2022
#VisualAbstract: Nonoperative management of uncomplicated acute appendicitis comparable to appendectomy but leads to increased length of stay and disease recurrence
StudyGraphics

#VisualAbstract: Thrombectomy alone is inferior to thrombectomy plus alteplase for acute ischemic stroke

August 5, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

Intravenous tenecteplase non-inferior to alteplase for thrombolysis in acute ischemic stroke

July 27, 2022
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Chronic Disease

Bridging therapy is superior to direct thrombectomy within 4.5 hours of acute ischemic stroke

July 20, 2022
Next Post
Pediatric palliative care outcome measures often miss quality of life

Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

Novel coronavirus identified from patients with pneumonia in Wuhan, China

High-flow oxygen therapy reduces intubation requirements and decreases recovery time in severe COVID-19 infections compared to conventional oxygen therapy

Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women

Intervention programs significantly decrease dating violence in adolescents

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ciprofol comparable to propofol for general anesthesia induction for gynecological surgery
  • Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
  • Type of compensation model influences gender pay gap in primary care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.